9 research outputs found
Chiral Modulations in Curved Space II: Conifold Geometries
In this paper, we extend our previous analysis concerning the formation of
inhomogeneous condensates in strongly-coupled fermion effective field theories
on curved spaces and include the case of conifold geometries that represent the
simplest tractable case of manifolds with curvature singularities. In the
set-up considered here, by keeping the genuine thermodynamical temperature
constant, we may single out the role that curvature effects play on the
breaking/restoration of chiral symmetry and on the appearance of inhomogeneous
phases. The first goal of this paper is to construct a general expression of
the finite temperature effective action for inhomogeneous condensates in the
case of four-fermion effective field theories on conifold geometries with
generic Riemannian smooth base (generalised cones). The other goal is to
implement numerically the above formal results and construct self-consistent
solutions for the condensate. We explicitly show that the condensate assumes a
kink-like profile, vanishing at the singularity that is surrounded by a bubble
of restored chiral symmetry phase.Comment: 14 pages; 4 figure
7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure
Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure
Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori Infection
A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori
Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone
BACKGROUND:
The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate.
METHODS:
In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month. Patients were excluded from the trial if they had a history of life-threatening or unstable asthma. The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization). Noninferiority of fluticasone-salmeterol to fluticasone alone was defined as an upper boundary of the 95% confidence interval for the risk of the primary safety end point of less than 2.0. The efficacy end point was the first severe asthma exacerbation.
RESULTS:
Of 11,679 patients who were enrolled, 67 had 74 serious asthma-related events, with 36 events in 34 patients in the fluticasone-salmeterol group and 38 events in 33 patients in the fluticasone-only group. The hazard ratio for a serious asthma-related event in the fluticasone-salmeterol group was 1.03 (95% confidence interval [CI], 0.64 to 1.66), and noninferiority was achieved (P=0.003). There were no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthma-related intubation. The risk of a severe asthma exacerbation was 21% lower in the fluticasone-salmeterol group than in the fluticasone-only group (hazard ratio, 0.79; 95% CI, 0.70 to 0.89), with at least one severe asthma exacerbation occurring in 480 of 5834 patients (8%) in the fluticasone-salmeterol group, as compared with 597 of 5845 patients (10%) in the fluticasone-only group (P<0.001).
CONCLUSIONS:
Patients who received salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of serious asthma-related events than did those who received fluticasone alone. Patients receiving fluticasone-salmeterol had fewer severe asthma exacerbations than did those in the fluticasone-only group